Table 3.
Probability of overall survival and disease-free survival at 5 and 10 years according to the demographic, clinical and pathological variables of sporadic colorectal cancer patients
| Variable | Overall survival (%) | p | Disease-free survival (%) | p | ||
|---|---|---|---|---|---|---|
| 5-y | 10-y | – | 5-y | 10-y | ||
| Survival | 83.9 | 77.1 | – | 77.4 | 77.4 | – |
| Gender | ||||||
| Male | 88.3 | 79.5 | 0.220 | 77.6 | 77.6 | 0.952 |
| Female | 78.3 | 71.8 | 77.3 | 77.3 | ||
| Age group (years) | ||||||
| < 65 | 79.1 | 72.5 | 0.248 | 68.8 | 68.8 | 0.039 |
| ≥ 65 | 88.9 | 82.1 | 86.7 | 86.7 | ||
| Topography | ||||||
| Colon | 83.3 | 74.4 | 0.430 | 75.7 | 75.7 | 0.403 |
| Upper rectal | 86.7 | 86.7 | 86.7 | 86.7 | ||
| CEA | ||||||
| Normal (<5.0) | 90.0 | 84.0 | 0.03 | 83.9 | 83.9 | 0.014 |
| Increased (>5.0) | 66.8 | 58.5 | 59.4 | 59.4 | ||
| T stage | ||||||
| T1-T2 | 95.7 | 95.7 | <0.001 | 97.9 | 97.9 | <0.001 |
| T3-T4 | 72.1 | 40.1 | 56.7 | 56.7 | ||
| N stage | ||||||
| N0 | 94.9 | 94.9 | <0.001 | 91.2 | 91.2 | <0.001 |
| N+ | 66.6 | 35.5 | 55.8 | 55.8 | ||
| M stage | ||||||
| M0 | 90.1 | 90.1 | <0.001 | 86.1 | 86.1 | <0.001 |
| M+ | 49.0 | 0 | 28.6 | 28.6 | ||
| Histological grade | ||||||
| Well differentiated | 87.5 | 12.5 | 0.126 | 87.5 | 87.5 | 0.026 |
| Moderately differentiated | 53.3 | 0 | 78.8 | 78.2 | ||
| Poorly differentiated | 0 | 0 | 40.0 | 40.0 | ||
| Blood embolization | ||||||
| No | 85.6 | 78.6 | 0.002 | 80.0 | 80.0 | <0.001 |
| Yes | 33.3 | 0 | 0 | 0 | ||
| Lymphatic embolization | ||||||
| No | 85.1 | 60.3 | 0.151 | 80.3 | 80.3 | 0.079 |
| Yes | 76.9 | 0 | 58.3 | 58.3 | ||
| Perineural invasion | ||||||
| No | 84.6 | 84.6 | 0.032 | 79.8 | 79.8 | 0.108 |
| Yes | 0 | 0 | 55.6 | 55.6 | ||
| KRAS | ||||||
| Wild | 79.8 | 79.8 | 0.310 | 74.2 | 74.2 | 0.710 |
| Mutated | 61.9 | 61.9 | 66.7 | 66.7 | ||
| Primer Pair 1- ERβ1, ERβ2 and ERβ4 isoforms* | ||||||
| > −7.2 | – | – | 76.4 | 76.4 | 0.301 | |
| ≤ −7.2 | – | – | 100 | 100 | ||
| > −3.2 | 87.5 | 87.5 | 0.361 | – | – | |
| ≤ −3.2 | 82.7 | 73.5 | – | – | ||
| Primer Pair 2 - ERβ1 and ERβ5 isoforms* | ||||||
| > −4.5 | – | – | 62.5 | 62.5 | 0.012 | |
| ≤ −4.5 | – | – | 85.3 | 85.3 | ||
| > −7.6 | 81.6 | 81.6 | 0.118 | – | – | |
| ≤ −7.6 | 100 | 100 | – | – | ||
| Primer Pair 3 - ERβ 2 isoform* | ||||||
| > −4.5 | – | – | 76.8 | 76.8 | 0.609 | |
| ≤ −4.5 | – | – | 85.7 | 85.7 | ||
| > −3.2 | 82.4 | 75.2 | 0.187 | – | – | |
| ≤ −3.2 | 100 | 100 | – | – | ||
p-value obtained by the log-rank test. Statistically significant p values (p < 0.05) are shown in bold type. *The cut-off for relative gene expression (log2) was determined using the log-rank test (maximally selected rank statistics in R) [24]